Hypoxia-inducible CAR expression: An answer to the on-target/off-tumor dilemma?

Kosti, 2021, Hypoxia-Sensing CAR T-Cells Provide Safety and Efficacy in Treating Solid Tumors, Cell Reports Medicine, 2, 10.1016/j.xcrm.2021.100227 Roybal, 2016, Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits, Cell, 164, 770, 10.1016/j.cell.2016.01.011 Sakemura, 2016, A Tet-On Inducible System for Controlling CD19-Chimeric Antigen Receptor Expression upon Drug Administration, Cancer Immunol. Res., 4, 658, 10.1158/2326-6066.CIR-16-0043 Sukumaran, 2018, Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment, Cancer Discov., 8, 972, 10.1158/2159-8290.CD-17-1298 Brown, 2004, Exploiting tumour hypoxia in cancer treatment, Nat. Rev. Cancer, 4, 437, 10.1038/nrc1367 Vaupel, 2007, Hypoxia in cancer: significance and impact on clinical outcome, Cancer Metastasis Rev., 26, 225, 10.1007/s10555-007-9055-1 Semenza, 2012, Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy, Trends Pharmacol. Sci., 33, 207, 10.1016/j.tips.2012.01.005 Juillerat, 2017, An oxygen sensitive self-decision making engineered CAR T-cell, Sci. Rep., 7, 39833, 10.1038/srep39833 Richman, 2018, High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model, Cancer Immunol. Res., 6, 36, 10.1158/2326-6066.CIR-17-0211 Moghimi, 2021, Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma, Nat. Commun., 12, 511, 10.1038/s41467-020-20785-x